Cost-effectiveness of expanding the target population of biennial screening for breast cancer from ages 50–69 to 45 and/or 74: A cohort modelling study in the Finnish setting

Filip Siegfrids (), Sirpa Heinävaara, Tytti Sarkeala, Laura Niinikoski and Juha Laine
Additional contact information
Filip Siegfrids: Finnish Cancer Registry
Sirpa Heinävaara: Finnish Cancer Registry
Tytti Sarkeala: Finnish Cancer Registry
Laura Niinikoski: Finnish Cancer Registry
Juha Laine: InFLAMES, University of Turku

Health Economics Review, 2025, vol. 15, issue 1, 1-13

Abstract: Abstract Background Within Finland’s breast cancer screening program, all women aged 50–69 are invited to biennial screening. Current European guidelines recommend screening in ages 45–49 and 70–74 conditional upon, inter alia, demonstrated context-specific cost-effectiveness. This study aims to determine the cost-effectiveness of expanding the target population of biennial screening to ages 45 and/or 74, compared to the current national breast cancer screening strategy, in the Finnish setting. Methods Screening strategies’ costs and quality-adjusted life years (QALY), aggregated over a lifetime horizon for the population simulated through a decision-analytic model, allow for comparison through incremental cost-effectiveness ratios. The model, using a Markov cohort simulation approach, was adapted to the cancer stage classification system used by the Finnish Cancer Registry (FCR) and calibrated to observed metrics in the Finnish female population. The analysis was conducted from a limited societal perspective, using a discount rate of 3% for costs and outcomes. Sensitivity analyses were performed to assess decision uncertainty, using an implicit willingness-to-pay (WTP) threshold range of €25 000–50 000 per incremental QALY. Results Compared to the current national screening strategy, both strategies with a starting age of 45 were cost-effective at the WTP-threshold of €50 000 per incremental QALY. Biennial screening in ages 45–69 was also cost-effective at €25 000 per QALY and demonstrated the highest probability of cost-effectiveness of all screening strategies over the whole WTP-threshold range of €25 000–50 000 per QALY. Biennial screening in ages 50–74 was dominated by all strategies over the threshold range. Conclusions Expanding the national screening strategy target population age is likely to produce net health benefits to acceptable costs, insofar as women aged 45–49 are covered by the expansion. Only expanding the target population to age 74 is unlikely to be cost-effective, given a WTP-threshold range of €25 000–50 000 per incremental QALY.

Keywords: Cost-effectiveness; Breast cancer; Screening; Finland (search for similar items in EconPapers)
Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-025-00628-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:15:y:2025:i:1:d:10.1186_s13561-025-00628-5

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-025-00628-5

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().